Goldman Sachs analyst Rajan Sharma has maintained their neutral stance on HALO stock, giving a Hold rating on September 19. Rajan Sharma has given his Hold rating due to a
Goldman Sachs analyst Rajan Sharma has maintained their neutral stance on HALO stock, giving a Hold rating on September 19. Rajan Sharma has given his Hold rating due to a
Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Halozyme (HALO – Research Report). The associated price target remains the same with $72.00. Jason Butler has given
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
JPMorgan שינו את המלצתם לגבי Halozyme Therapeutics מ”קנייה” ל”החזקה”. הם העלו את מחיר היעד ל-57 דולר מהמחיר הקודם של 52 דולר. הסיבה לשינוי זה היא בשל ערכו של המניה, שכבר
JPMorgan downgraded Halozyme Therapeutics to Neutral from Overweight with a price target of $57, up from $52. The analyst cites valuation for the downgrade with the shares up 69% year-to-date.